ATAD1 and malaria: Malaria vaccines targeting erythrocytic stage antigens, such as merozoite surface protein 1 (MSP1), apical membrane antigen 1 (AMA1), glutamate-rich protein (GLURP)/merozoite surface protein 3 (MSP3), Combo B [MSP1, merozoite surface protein 2 (MSP2), and ring-infected erythrocyte surface antigen (RESA)], and reticulocyte-binding protein homolog 5 (RH5), have been evaluated in clinical trials.